Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor

J Med Chem. 2013 Jul 11;56(13):5247-60. doi: 10.1021/jm4006059.

Hui-Yi Shiao ¹, Mohane Selvaraj Coumar, Chun-Wei Chang, Yi-Yu Ke, Ya-Hui Chi, Chang-Ying Chu, Hsu-Yi Sun, Chun-Hwa Chen, Wen-Hsing Lin, Ka-Shu Fung, Po-Chu Kuo, Chin-Ting Huang, Kai-Yen Chang, Cheng-Tai Lu, John T A Hsu, Chiung-Tong Chen, Weir-Torn Jiaang, Yu-Sheng Chao, Hsing-Pang Hsieh

Affiliations

Affiliation

1 Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes , 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC.

PMID: 23808327 DOI: 10.1021/jm4006059

Abstract

Ligand efficiency (LE) and lipophilic efficiency (LipE) are two important indicators of "drug-likeness", which are dependent on the molecule's activity and physicochemical properties. We recently reported a furano-pyrimidine Aurora Kinase Inhibitor 4 (LE = 0.25; LipE = 1.75), with potent activity in vitro; however, 4 was inactive in vivo. On the basis of insights obtained from the X-ray co-crystal structure of the lead 4, various solubilizing functional groups were introduced to optimize both the activity and physicochemical properties. Emphasis was placed on identifying potential leads with improved activity as well as better LE and LipE by exercising tight control over the molecular weight and lipophilicity of the molecules. Rational optimization has led to the identification of Aurora Kinase Inhibitor 27 (IBPR001; LE = 0.26; LipE = 4.78), with improved in vitro potency and physicochemical properties, resulting in an in vivo active (HCT-116 colon Cancer xenograft mouse model) Anticancer agent.

Name
Email *

	Sorry, but the email address you supplied was invalid.